Drugs / Human Factor XIII Concentrate
Human Factor XIII Concentrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02551042 | Sep 2015 → Sep 2016 | systemic sclerosis | University College, London | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Factor XIII Concentrate | “The purpose of this study is to see how effective the study drug Human Factor XIII Concentrate is in treating patients who have these and other common manifestation of Scleroderma.” NCT02551042 ↗ |
| Known as | FibrogamminP | “Fibrogammin®P, coagulation factor XIII concentrate (Human)” NCT02551042 ↗ |
| Known as | FXIII | “Administration of human Factor XIII (FXIII) concentrate in patients with scleroderma demonstrated promising results in the 1980s and 1990s” NCT02551042 ↗ |
| Modality | Protein / enzyme biologic | “human Factor XIII (FXIII) concentrate” NCT02551042 ↗ |
| Route | Intravenous | “Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion” NCT02551042 ↗ |